Secondary Cancers After Hodgkin’s Disease in the Matched Patients (PRD, PSD, and R1) Included in the Risk-Factor Analysis (External Analysis)
| . | 393 Grafted Patients (PRD/PSD/R1) . | 1,179 Ungrafted Patients (PRD/PSD/R1) . | RR (95% CI), P Value . |
|---|---|---|---|
| MDS/AML | 6 (0/3/3)* | 18 (1/6/11) | 2.54 (0.98-6.61), .056 |
| Non-Hodgkin lymphoma | 1 (0/0/1) | 3 (0/1/2) | 2.27 (0.21-24.06), .50 |
| Solid tumors | 8 (0/2/6)3-151 | 15 (2/4/9) | 5.19 (2.03-13.3), .001 |
| All second cancers | 15 (0/5/10) | 36 (3/11/22) | 3.47 (1.83-6.56), <.001 |
| Median time since diagnosis (range), in months | 50 (32-134) | 65 (12-200) | |
| Median time since ASCT or last treatment (range), in months | 28 (9-62) | 50 (12-170) |
| . | 393 Grafted Patients (PRD/PSD/R1) . | 1,179 Ungrafted Patients (PRD/PSD/R1) . | RR (95% CI), P Value . |
|---|---|---|---|
| MDS/AML | 6 (0/3/3)* | 18 (1/6/11) | 2.54 (0.98-6.61), .056 |
| Non-Hodgkin lymphoma | 1 (0/0/1) | 3 (0/1/2) | 2.27 (0.21-24.06), .50 |
| Solid tumors | 8 (0/2/6)3-151 | 15 (2/4/9) | 5.19 (2.03-13.3), .001 |
| All second cancers | 15 (0/5/10) | 36 (3/11/22) | 3.47 (1.83-6.56), <.001 |
| Median time since diagnosis (range), in months | 50 (32-134) | 65 (12-200) | |
| Median time since ASCT or last treatment (range), in months | 28 (9-62) | 50 (12-170) |
*Two refractory anemia with an excess of blasts, one refractory anemia, one AML M2 and one unclassifiable AML.
In the field of RT, one pleural and one lung carcinoma, borderline, one breast and one pharynx.